(Q33957200)

30 July 2017

1 reference

title

The use of mycophenolate mofetil in transplant recipients (English)

1 reference

30 July 2017

T S Mele

1

1 reference

PubMed ID

10878291

30 July 2017

P F Halloran

series ordinal

2

1 reference

30 July 2017

1 May 2000

1 reference

30 July 2017

1 reference

30 July 2017

47

1 reference

30 July 2017

215-245

1 reference

30 July 2017

2-3

1 reference

Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Risk factors for chronic rejection in renal allograft recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Early versus late acute renal allograft rejection: impact on chronic rejection.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolic Acid: an Anti-cancer Compound with Unusual Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Cyclosporin in therapeutic doses increases renal allograft vascular resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

The inhibition of nucleic acid synthesis by mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Control of phosphoribosylpyrophosphate synthesis in human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil rescue therapy in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Chronic renal allograft rejection: no response to mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil in pancreas transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Treatment Of Psoriasis With Oral Mycophenolic Acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Tacrolimus rescue therapy for renal allograft rejection--five-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

How one thing has led to another

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Selectins: interpreters of cell-specific carbohydrate information during inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Bioavailability improvement of mycophenolic acid through amino ester derivatization

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

The impact of an acute rejection episode on long-term renal allograft survival (t1/2)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Immunosuppressive effect of mycophenolic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Human type I and II IMP dehydrogenases as drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Tumors of the immunocompromised patient

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

RS-61443--a new, potent immunosuppressive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

RS-61443--a phase I clinical trial and pilot rescue study

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Antitumor activity of mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Reduction of Ribonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Acute rejection and renal allograft outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study G

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolic acid: antiviral and antitumor properties

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900190-9

7 January 2021

10.1016/S0162-3109(00)00190-9

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10878291